AstraZeneca 4Q Revenues: $5.8 billion (+3%) 4Q Earnings: $1.3 billion (-31%) FY Revenues: $22.5 billion (-2%) FY Earnings: $2.9 billion (-16%) Comments: For the year, Product Sales were down 5% to $20.2 billion. Crestor sales declined 30% to $2.4 billion and Seroquel XR sales declined 55% to $332 million due to loss of exclusivity in the U.S. Brilinta and Farxiga sales were $1.1 billion for the year, up 29%. Symbicort sales were down 6% to $2.8 billion. Pulmicort sales were up 11% to $1.2 b...